STING agonists induce the expression of PD-L1 on the surface of tumor cells, thereby inhibiting specific killing of tumor antigens, providing a rationale for the combined use of STING agonists with PD-1/PD-L1 antibodies in tumor immunotherapy [21,22]. The gene discussed is STING1; the disease is neoplasm.